Search research articles
Contact Us
Filters
Showing results (1-10 of 121) with videos related to
Page
of 13
Sort By:
Journal of Managed Care Pharmacy : JMCP
|
March 25, 2010
Variation in prescriber responses to drug safety alert messages: disease, symptom, or red herring?
Daniel A Ollendorf
Expert Review of Pharmacoeconomics & Outcomes Research
|
November 5, 2023
Revival? Prospects for a return to comprehensive and coordinated health technology assessment in America
Daniel A Ollendorf
BMJ (Clinical Research Ed.)
|
February 5, 2020
Histology independent cancer drugs: the drug makers' responsibility
Daniel A Ollendorf
International Journal of Technology Assessment in Health Care
|
June 25, 2015
VOLUME 31: HTA'S EVOLUTION: FROM CONSUMER TO HONEST BROKER TO ENGAGED COLLABORATOR
Daniel A Ollendorf
American Journal of Therapeutics
|
November 24, 2006
Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting
Daniel A Ollendorf, Loren Lidsky
Health Affairs Scholar
|
October 6, 2025
How to make one line in the FDA Commissioner's new drug review program into a force for affordable access for patients
Sarah K Emond, Daniel A Ollendorf
Journal of Comparative Effectiveness Research
|
December 19, 2013
Through the looking glass: making the design and output of economic models useful for setting medical policy
Daniel A Ollendorf, Steven D Pearson
Medical Care
|
May 18, 2010
An integrated evidence rating to frame comparative effectiveness assessments for decision makers
Daniel A Ollendorf, Steven D Pearson
International Journal of Technology Assessment in Health Care
|
July 15, 2021
Considering and communicating uncertainty in health technology assessment
Rebecca Trowman, Alicia Powers, Daniel A Ollendorf
International Journal of Technology Assessment in Health Care
|
August 5, 2020
Principles for deliberative processes in health technology assessment
Kenneth Bond, Rebecca Stiffell, Daniel A Ollendorf
Page
of 13
Search research articles
Search
Showing results (1-10 of 121) with videos related to
Sort By:
Page
of 13
Journal of Managed Care Pharmacy : JMCP
|
March 25, 2010
Variation in prescriber responses to drug safety alert messages: disease, symptom, or red herring?
Daniel A Ollendorf
Expert Review of Pharmacoeconomics & Outcomes Research
|
November 5, 2023
Revival? Prospects for a return to comprehensive and coordinated health technology assessment in America
Daniel A Ollendorf
BMJ (Clinical Research Ed.)
|
February 5, 2020
Histology independent cancer drugs: the drug makers' responsibility
Daniel A Ollendorf
International Journal of Technology Assessment in Health Care
|
June 25, 2015
VOLUME 31: HTA'S EVOLUTION: FROM CONSUMER TO HONEST BROKER TO ENGAGED COLLABORATOR
Daniel A Ollendorf
American Journal of Therapeutics
|
November 24, 2006
Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting
Daniel A Ollendorf, Loren Lidsky
Health Affairs Scholar
|
October 6, 2025
How to make one line in the FDA Commissioner's new drug review program into a force for affordable access for patients
Sarah K Emond, Daniel A Ollendorf
Journal of Comparative Effectiveness Research
|
December 19, 2013
Through the looking glass: making the design and output of economic models useful for setting medical policy
Daniel A Ollendorf, Steven D Pearson
Medical Care
|
May 18, 2010
An integrated evidence rating to frame comparative effectiveness assessments for decision makers
Daniel A Ollendorf, Steven D Pearson
International Journal of Technology Assessment in Health Care
|
July 15, 2021
Considering and communicating uncertainty in health technology assessment
Rebecca Trowman, Alicia Powers, Daniel A Ollendorf
International Journal of Technology Assessment in Health Care
|
August 5, 2020
Principles for deliberative processes in health technology assessment
Kenneth Bond, Rebecca Stiffell, Daniel A Ollendorf
Page
of 13